Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700023106

Trial Profile

Clinical Trials Insight: 700023106

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2008

At a glance

  • Drugs NGD 4715 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Neurogen Corporation
  • Most Recent Events

    • 08 Jan 2008 Status changed from planning to completed.
    • 08 Jan 2008 The follow-up portion of this study has been completed.
    • 08 Nov 2007 Neurogen extended this study in order to explore NGD 4715's effects on lipid levels and potential drug-drug interactions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top